Home > Companies > NAMM California

NAMM California

North American Medical Management (NAMM) California, Inc., part of OptumCare®, develops and manages provider networks, offering a full range of services to assist physicians and other providers in their managed care and business operations (the “Clients”). For 25 years, NAMM has been an innovator in health care with a track record for quality, financial stability, extraordinary services and superior electronic capabilities. NAMM is well positioned to continually invest in its infrastructure and systems for the benefit of its Clients and to accommodate the impending changes that will come forth from healthcare reform. The NAMM Clients represent a network of over 600 primary care physicians and 1,500 specialists and work with the premier hospitals in their respective markets.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

Evolution and Core Processes in Gene Expression

Conference

BIO IMPACT 2022

Conference

Emerging role of biomarkers for cardiovascular risk assessment in T2DM and optimisation of cardioprotective treatment: current evidence and future trends

Webinar

5th International Conference on Glycobiology

Conference

Applying Lean Six Sigma to Healthcare Processes

Webinar

Ischaemic stroke

Webinar

Related News

INDUSTRIAL IMPACT

LUMMUS AND SYNTHOS ADVANCE BIO-BUTADIENE TECHNOLOGY DEVELOPMENT TO PRODUCE SUSTAINABLE RUBBER

Lummus Technology, LLC | February 14, 2022

Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project. Given the confidence in the technology and the strong market demand for ren...

RESEARCH

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

MEDICAL

WESTLAKE VILLAGE BIOPARTNERS LAUNCHES TWO NEW FUNDS TOTALING $500 MILLION TO BUILD AND INVEST IN PROMISING LIFE SCIENCES COMPANIES

Westlake Village BioPartners | December 15, 2020

Westlake Village BioPartners today announced the launch of two new funds totaling $500 million to build and put resources into promising life sciences organizations with transformative therapeutic technologies. The first fund, known as Opportunity 1, is $70 million and permits Westlake to contribute extra Series B or later-round capital into promising organizations they incubated or invested into with their original fund, Westlake BioPartners 1 (WBP1). One example is a begin...

MEDICAL

ARUNA BIO ADVANCES THERAPEUTIC DEVELOPMENT FOR TRAUMATIC BRAIN INJURY

Aruna Bio | June 01, 2022

Aruna Bio, Inc., a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced that it has received funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health of Health to advance AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI). The succ...

INDUSTRIAL IMPACT